Other commonly identified genetic mutations in NSCLC include rearrangement of the anaplastic lymphoma kinase (ALK) oncogene (present in up to 5% of NSCLCs), the Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (present in 20–30% of NSCLCs), and the tumor protein p53 (TP53) gene (up to 60% of cases) [6,7]. Here, KRAS is linked to non-small cell lung carcinoma.